The present disclosure relates to a process for obtaining an ultrapure polymer by simply and effectively removing unreacted residual monomer in polymer, which is generated during production of a biodegradable polymer such as polylactic acid or derivatives thereof.

A process to produce a polyester polymer by polymerization of a cyclic polyester oligomer composition comprising a cyclic polyester oligomer having furanic units in the presence of a plasticizer, as well as the polyester polymer obtained thereby.

A process to produce a polyester polymer by polymerization of a cyclic polyester oligomer composition comprising a cyclic polyester oligomer having furanic units in the presence of a plasticizer, as well as the polyester polymer obtained thereby.

A polyester obtained by the esterification of terephthalic acid and ethylene glycol and the polycondensation catalysed by a mixture of magnesium ethylene glycol and antimony ethylene glycol followed by granulation. In the polyester sections, the carboxyl end group is less than 15 mol/t, the mass percentage of oligomer is lower than 0.5%, and weight percentage of diethylene glycol is lower than 0.5%.

A polyester obtained by the esterification of terephthalic acid and ethylene glycol and the polycondensation catalysed by a mixture of magnesium ethylene glycol and antimony ethylene glycol followed by granulation. In the polyester sections, the carboxyl end group is less than 15 mol/t, the mass percentage of oligomer is lower than 0.5%, and weight percentage of diethylene glycol is lower than 0.5%.

A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced initial burst effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced initial burst effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

The present invention relates to a device and also to a method for separating and recovering a cyclic diester, in particular dilactide or glycolide from polymer melts which include the cyclic diester as impurity. The device and also the method according to the invention allow recovery of the cyclic diester with a high yield and at the same time high purity.

The present invention relates to a device and also to a method for separating and recovering a cyclic diester, in particular dilactide or glycolide from polymer melts which include the cyclic diester as impurity. The device and also the method according to the invention allow recovery of the cyclic diester with a high yield and at the same time high purity.

Disclosed is a method for preparing a fully-degradable non-woven fabric by spun-bonding, including: (S1) preparation of a poly(caprolactone-co-lactide acid) (P(CL-co-LA)); (S2) preparation of a copolymerized-modified poly(lactide acid) (PLA); and (S3) preparation of a full-degradable non-woven fabric using a spun-bond method. In this disclosure, the PLA is modified in gradient several times to prepare the full-degradable non-woven fabric in combination with an optimized spun-bonding method.